Galenica Reports 5.7% Sales Increase, Confirms 2026 Outlook

Galenica AG experienced a 5.7% sales increase to CHF 3,172.0 million in the first nine months of 2026. The growth was fueled by the pharmacy business and home care sector, alongside a positive performance in the Diagnostics segment. Despite temporary restrictions in the wholesale business due to an ERP migration, Galenica forecasts renewed growth momentum in the fourth quarter.

The pharmacy segment grew its net sales by 6.2%, attributable to rising demand for prescription medications. In contrast, the Products & Brands segment faced a 7.2% decline, influenced by seasonal factors.

Home care and Diagnostics continued their positive trends, with home care emerging as a crucial growth driver. The successful ERP migration at Galexis promises increased automation and efficiency.

Galenica reaffirms its 2026 sales growth forecast of 5-7%, with adjusted EBIT expected to rise by 6-8%. A dividend matching the previous year is projected.